Novo Nordisk's oral obesity drug Wegovy pill has surpassed 3 million cumulative prescriptions in the U.S. since its January launch, with over 80% of new patients being GLP-1 treatment-naïve. This signals that oral therapies are expanding the obesity market beyond injectable alternatives, reshaping supply-chain dynamics for distributors and clinics eyeing next-generation weight management products.
Market signal
Novo Nordisk reported that Wegovy pill prescriptions have exceeded 3 million since its U.S. launch in January, averaging one prescription every five seconds. Over 80% of new patients had no prior GLP-1 treatment experience, indicating that oral obesity drugs are attracting a previously untreated patient population. The company's Q1 2025 sales for the pill reached approximately $350 million, surpassing market expectations and prompting an upward revision of its full-year outlook.
Competitor landscape
Eli Lilly launched its oral GLP-1 drug Foundayo (orforglipron) in the U.S. in April 2025. Unlike Wegovy pill, Foundayo is a non-peptide small molecule that can be taken without food or water restrictions, offering greater convenience. At ADA 2026, Lilly presented ATTAIN-1 Phase 3 data showing weight reductions of 12.8% to 14.4% across premenopausal, perimenopausal, and postmenopausal women at the highest dose (17.2 mg). This highlights a shift from average weight loss metrics to subgroup-specific efficacy.
Emerging players and mechanisms
Chinese biotech Ascletis Pharma unveiled data at ADA 2026 for three oral candidates: ASC30 (oral GLP-1), ASC39 (oral amylin receptor agonist), and ASC37 (oral GLP-1/GIP/glucagon triple agonist). ASC30 achieved placebo-adjusted mean weight loss of 5.4% to 7.7% in a 13-week Phase 2 trial, with no plateau at week 13. The company plans to initiate global Phase 3 after FDA discussions in Q3 2025. ASC39 opens potential for fixed-dose combinations, while ASC37 expands into multi-mechanism therapy.
Sourcing context
South Korean developers are repositioning their pipelines amid the oral GLP-1 race. Ildong Pharmaceutical's subsidiary Yunovia is developing ID110521156, an oral small-molecule GLP-1 agonist. In a Phase 1 multiple-dose trial, the 200 mg group showed mean weight loss of 9.9% at week 4, with 87.5% of subjects achieving ≥5% weight loss. The drug shows no accumulation and limited food effect, positioning it against Lilly's orforglipron. However, long-term obesity patient data is still needed.
What buyers should watch
Hanmi Pharmaceutical is advancing next-generation pipelines including HM15275, muscle-preserving HM17321, and MASH candidate epinopegdutide (licensed to MSD). D&D Pharmatech focuses on MASH and metabolic disease linkages. Peptron and InventageLab hold long-acting injectable platform technologies, which may retain demand even as oral options grow. An industry insider noted: "The era of relying solely on GLP-1 pipelines for technology export or valuation is fading. Global pharma is expanding into oral formulations, multi-mechanism therapies, and comorbid indications. Korean firms must prove clinical value beyond weight loss."
Source: Read the original report | Published: June 08, 2026